Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02914600 · ClinicalTrials.gov registry record · Phase 3
Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease
A Phase 3 study, sponsored by Lakefront Biotherapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,188
- Enrollment target
NCT02914600: Clinical Trial Phase 3 study, sponsored by Lakefront Biotherapeutics.
NCT02914600 is a Phase 3 study that was terminated before completion, run by Lakefront Biotherapeutics. The registered enrollment target is 1,188 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (54% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02914600, a Phase 3 study, was terminated before completion, sponsored by Lakefront Biotherapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,188 participants
- Enrollment target
Study Summary
The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in Crohn's disease (CD).
Primary Outcome
An AE was defined as any untoward medical occurrence in a participant administered a study drug, and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug whether or not considered related to the study drug. Treatment-emergent adverse events (TEAEs) were defined as 1 or both of the fo
Interventions
- DRUG Placebo
- DRUG Filgotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,188 participants |
| Start Date | 2017-03-17 |
| Est. Completion | 2023-08-01 |
| Phase | Phase 3 |
Why NCT02914600 stopped before completion
NCT02914600 is an interventional study that assigns participants to a tested intervention. Its 1,188 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (54% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02914600 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02914600 about?
NCT02914600 is a clinical study titled "Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease". The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in Crohn's disease (CD).
What is the current status of trial NCT02914600?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,188 participants. The study started on 2017-03-17. Estimated completion is 2023-08-01.
What interventions are being tested in trial NCT02914600?
The interventions under investigation include: Placebo (DRUG), Filgotinib (DRUG).
Who is sponsoring clinical trial NCT02914600?
This trial is sponsored by Lakefront Biotherapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02914600's enrollment target sits among peer trials
1,188 229th of 2000 higher than 1,770 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05580419 · 1,188 participants · NA
Impact of 4PCP on Practitioner and Patient Outcomes
- NCT06290869 · 1,188 participants · Phase 3
Tobacco Education and Lung Health Study (TEAL)
- NCT04293562 · 1,186 participants · Phase 3
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- NCT07286058 · 1,182 participants · Phase 3
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI